These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30366616)

  • 1. Cell, tissue and gene products with marketing authorization in 2018 worldwide.
    Cuende N; Rasko JEJ; Koh MBC; Dominici M; Ikonomou L
    Cytotherapy; 2018 Nov; 20(11):1401-1413. PubMed ID: 30366616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products.
    Ikonomou L; Cuende N; Forte M; Grilley BJ; Levine AD; Munsie M; Rasko JEJ; Turner L; Bidkhori HR; Ciccocioppo R; Grignon F; Srivastava A; Weiss DJ; Zettler P; Levine BL;
    Cytotherapy; 2023 Sep; 25(9):920-929. PubMed ID: 37517865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT).
    Sanchez-Guijo F; Vives J; Ruggeri A; Chabannon C; Corbacioglu S; Dolstra H; Farge D; Gagelmann N; Horgan C; Kuball J; Neven B; Rintala T; Rocha V; Sanchez-Ortega I; Snowden JA; Zwaginga JJ; Gnecchi M; Sureda A
    Cytotherapy; 2024 Jul; 26(7):681-685. PubMed ID: 38416085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
    Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
    Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proceedings of the signature series symposium "cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy," international society for cellular therapies, montreal, canada, may 2, 2018.
    Piuzzi NS; Dominici M; Long M; Pascual-Garrido C; Rodeo S; Huard J; Guicheux J; McFarland R; Goodrich LR; Maddens S; Robey PG; Bauer TW; Barrett J; Barry F; Karli D; Chu CR; Weiss DJ; Martin I; Jorgensen C; Muschler GF
    Cytotherapy; 2018 Nov; 20(11):1381-1400. PubMed ID: 30316562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
    Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
    [No Abstract]   [Full Text] [Related]  

  • 9. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
    Marti A
    Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors (Review).
    Harrison RP; Chauhan VM
    Biointerphases; 2017 Dec; 13(1):01A301. PubMed ID: 29246035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelfth Annual Meeting of the French Society of Cell and Gene Therapy.
    Verhoeyen E; Gomez S; Galy A; Ayuso E; Midoux P; Pucéat M; Vassaux G; Cordelier P
    Hum Gene Ther; 2016 Jul; 27(7):555-8. PubMed ID: 27428658
    [No Abstract]   [Full Text] [Related]  

  • 13. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Regulation of Cell Therapy and Gene Therapy Products in Switzerland.
    Bukovac PK; Hauser M; Lottaz D; Marti A; Schmitt I; Schochat T
    Adv Exp Med Biol; 2023; 1430():41-58. PubMed ID: 37526841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
    Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
    Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.
    Choi M; Han E; Lee S; Kim T; Shin W
    Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell and gene therapy: a snapshot of investor perspectives.
    Moody J; Milligan WD; St Onge M; Goonewardene A; Rivers P
    Cytotherapy; 2021 Mar; 23(3):256-260. PubMed ID: 33281066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors.
    Harrison RP; Ruck S; Rafiq QA; Medcalf N
    Biotechnol Adv; 2018; 36(2):345-357. PubMed ID: 29278756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.